System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42293067 DOI: 10.3389/fneur.2026.1770966

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific.

Front Neurol 17:1770966

Authors: Charles Hua Chiang Siow, Shengyuan Yu, Surat Tanprawate, Shuu-Jiun Wang, Elspeth J Hutton, Byung-Kun Kim, Min Kyung Chu, Norihiro Suzuki, Wanakorn Rattanawong, Ka Sing Wong, Mi Ji Lee, Zhao Dong, Hebo Wang, Xianliang Li, Koichi Hirata, Takao Takeshima

Affiliations

  • The Brain Centre, Mt Elizabeth Novena Hospital, Singapore, Singapore.
  • Department of Neurology, Chinese PLA General Hospital, Beijing, China.
  • Department of Internal Medicine (Neurology Division), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • College of Medicine and Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Neuroscience, School of Translational Medicine, Monash University, Melborne, VIC, Australia.
  • Department of Neurology, Alfred Health, Melbourne, VIC, Australia.
  • Department of Neurology, Eulji University School of Medicine, Daejeon, Republic of Korea.
  • Department of Neurology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Shonan Keiiku Hospital, Fujisawa, Japan.
  • Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, Thailand.
  • Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Hebei General Hospital, Shijiazhuang, China.
  • Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Neurology, Dokkyo Medical University, Mibu, Tochigi, Japan.
  • Tominaga Hospital, Osaka, Japan.

Abstract

BACKGROUND

Although diagnostic criteria and treatment guidelines for migraine are well-established, care remains suboptimal due to frequent misdiagnosis and undertreatment. This Delphi consensus aimed to explore how clinicians in the Asia-Pacific region approach migraine diagnosis and management.

METHODS

This study used a modified-Delphi method, involving two rounds of surveys and a virtual scientific meeting with 14 headache-specialists from seven countries in Asia-Pacific. Consensus on statements was measured using a Likert scale ranging from 1 to 9, with consensus threshold set at 75%.

RESULTS

The study had 100% participation in both surveys, and the scientific meeting was attended by 64.3% of participants. Out of 21 closed-ended statements, 12 reached consensus. Notably, 93% of participants reported using only ICHD-3 for migraine diagnosis, and 79% found the criteria easy to apply. For the diagnosis of migraine, all participants evaluated migraine-related disability and depression; 93% anxiety, and 86% sleep disturbances. Neck pain and dizziness were recognised as migraine-associated symptoms by 93% of respondents, with 85% reporting that 25-75% of their patients experience neck pain. Anti-CGRP mAbs were considered effective and addressed unmet needs for chronic or episodic migraine by 86% of participants. Efficacy (100%) was the primary deciding factor in selecting a specific anti-CGRP mAb, followed by safety (93%) and tolerability (86%). Factors such as frequency of administration (43%), perceived wearing-off effect (43%), availability and reimbursement (57%), and cost (58%) were less influential in decision-making. While 79% of the participants would consider anti-CGRP mAbs as first-line treatment, 93% believed these therapies would improve safety, adherence, and compliance outcomes. Only 7% of the participants favoured the use of gepants. Participants unanimously supported the use of anti-CGRP mAbs in adolescents (13-17 years), but not in children (6-12 years).

CONCLUSION

Consensus was reached on key aspects of migraine diagnosis and management. Participants endorsed the ICHD-3 criteria as the diagnostic standard and favoured using headache diaries, followed by MIDAS and HIT-6 for assessment. Anti-CGRP mAbs were recognised as effective in addressing unmet needs in migraine prevention. The panel advised against using anti-CGRP mAbs in children under 12 due to insufficient evidence, highlighting the need for more paediatric data.

MeSH

Headache, Safety, Pain, Migraine Disorders, Surveys And Questionnaires, Diagnosis, Therapeutics, Child